Cytokinetics ticker

Author: rumm

August undefined, 2024

WebMar 4, 2024 · Today is shaping up negative for Cytokinetics, ... (ticker: BBBY) stock was down nearly 20% at 83 cents. In a reverse stock split, each outstanding share is converted into a fraction of the share. WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 …

Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Cut …

WebCytokinetics Inc. Annual stock financials by MarketWatch. View the latest CYTK financial statements, income statements and financial ratios. WebMar 6, 2024 · SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor ... trying not to love you nickelback

Cytokinetics receives FDA Complete Response Letter for …

WebCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential … WebApr 7, 2024 · Cytokinetics, Inc.’s trailing 12-month revenue is $94.6 million with a -411.2% profit margin. Year-over-year quarterly sales growth most recently was -96.4%. Analysts expect adjusted earnings to reach $-4.363 per share for the current fiscal year. Cytokinetics, Inc. does not currently pay a dividend. The Biotechnology and Medical … WebMar 31, 2024 · Cytokinetics Muscle Biology Therapies Home empowering muscle empowering lives Cytokinetics is committed to our mission of developing potential medicines that may improve the … phill.com obits

Bonnie Charpentier - Cytokinetics Insider Transactions

CYTK Cytokinetics Inc. Profile MarketWatch

WebBonnie Charpentier SVP Regulatory & Compliance at Cytokinetics, is currently unranked, see this insider's latest transactions. Top Stocks. Top Analyst Stocks Top Smart Score Stocks ... SVP Regulatory & Compliance at Cytokinetics, holds 0.00 shares in Cytokinetics (Ticker: CYTK). See the Hottest Stocks Based on Insider Trading > Bonnie ... WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating … phill collins wikipediaWebApr 13, 2024 · Issuer Name and Ticker or Trading Symbol CYTOKINETICS INC [ CYTK] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director: 10% Owner: X: Officer (give title below) Other (specify below) EVP Research & Development: 3. Date of Earliest Transaction (Month/Day/Year) phill cng home fueling station

"WebCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, … " - Cytokinetics ticker

Cytokinetics ticker

WebDec 30, 2024 · Cytokinetics, Incorporated is a late-stage biopharmaceutical company. It is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. WebJul 19, 2024 · The data suggest that Cytokinetics (ticker: CYTK) drug could become a potent rival to a similar investigational drug that Bristol Myers Squibb (BMY) acquired last …

Did you know?

Web2 days ago · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential … WebCytokinetics Stock Price Today NASDAQ CYTK Live Ticker - Investing.com Stock Screener United States Pre-Market World ADRs Stock Brokers Fed Rate Monitor Tool Cytokinetics Inc (CYTK)...

Webwww.cytonics.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology … WebFeb 28, 2024 · The US FDA has issued a Complete Response Letter to Cytokinetics ( NASDAQ: CYTK) for omecamtiv mecarbil for heart failure with reduced ejection fraction. Shares are down ~8% in post-market trading ...

WebCytokinetics, Incorporated (CYTK) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 34.71 -0.54 (-1.53%) As of 10:34AM EDT. Market open. WebApr 6, 2024 · Cytokinetics, Incorporated (CYTK) Stock Price Today, Quote & News Seeking Alpha Premium My Portfolio My Analysts Top Stocks Latest News Markets …

WebApr 6, 2024 · Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as …

WebMar 16, 2024 · Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle … phill corso jrWebDec 30, 2024 · Mizuho Securities analyst Salim Syed maintained a Buy rating on Cytokinetics (CYTK - Research Report) today and set a price target of $80.00. The … phill cosbyWeb1 day ago · Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil. 2d ago. Reuters. ... Emerson (ticker: EMR) confirmed Wednesday it was ... trying not to smoke cigaretteWebJun 27, 2024 · CYTK has a market cap of $4.05bn and a cash balance of $686mn. Research and development expenses for the first quarter 2024 were $45.9 million, while general and administrative expenses were $33.1... phillco construction kansas cityWebCytokinetics is a biopharmaceutical company developing therapies for debilitating diseases. South San Francisco, California, United States 251-500 Post-IPO Debt Public cytokinetics.com 1,449 Highlights Stock … phill cuzz one summer nightWebApr 5, 2024 · Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as … philldella yve photoWebFeb 17, 2024 · It is currently -18.08% from its 52-week high and 51.01% from its 52-week low. How much is Cytokinetics stock worth today? ( NASDAQ: CYTK) Cytokinetics currently has 94,631,001 outstanding shares. With Cytokinetics stock trading at $45.71 per share, the total value of Cytokinetics stock (market capitalization) is $4.33B. phill ding